Literature DB >> 8646227

Valvular heart disease in primary antiphospholipid syndrome (PAPS): clinical and morphological findings.

R García-Torres1, M C Amigo, A de la Rosa, A Morón, P A Reyes.   

Abstract

PURPOSE: To describe clinically and pathologically the valvular lesion of the primary antiphospholipid syndrome (PAPS). PATIENTS AND METHODS: We studied six patients with PAPS and valvulopathy. Four of them died and had autopsy and two had valvular replacement. The study comprised 18 heart valves, 16 from autopsy and two, one mitral and one aortic, resected at surgery.
RESULTS: Murmurs and echocardiographic findings kept correlation with gross pathology. Abnormalities were found in one or more valves in all patients including two of five aortic, two of five mitral, one of four pulmonary and two of four tricuspid. Co-existence of new and old lesions was observed. Pathologic findings included intravalvular thrombosis with focal necrosis, and hemorrhage, vascular proliferation, mild histiocytic/fibroblastic infiltration, laminated and verrucous fibrin deposits, laminated and/or nodular fibrosis, and focal calcification.
CONCLUSION: The PAPS valvular lesion consists mainly of superficial or intravalvular fibrin deposits and its subsequent organization: vascular proliferation, fibroblast influx, fibrosis and calcification. This results in valve thickening, fusion and rigidity leading to functional abnormalities. Inflammation is not a prominent feature of this lesion.

Entities:  

Mesh:

Year:  1996        PMID: 8646227     DOI: 10.1177/096120339600500111

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  8 in total

1.  Mitral valve plasty in systemic lupus erythematosus in the setting of antiphospholipid syndrome.

Authors:  M Yoshida; Y Sasako; J Kobayashi; K Minatoya; K Bando; S Kitamura
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2000-06

2.  Antiphospholipid syndrome and palindromic rheumatism: a new possible association.

Authors:  Tatiana Reitblat; Irena Litinsky; Dan Caspi; Ori Elkayam
Journal:  Rheumatol Int       Date:  2004-07-23       Impact factor: 2.631

3.  Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome.

Authors:  I Krause; S Lev; A Fraser; M Blank; M Lorber; L Stojanovich; J Rovensky; J Chapman; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2005-03-18       Impact factor: 19.103

Review 4.  Current treatment of antiphospholipid syndrome: lights and shadows.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Nat Rev Rheumatol       Date:  2015-06-30       Impact factor: 20.543

5.  A 37-Year-Old Man With Primary Antiphospholipid Syndrome Presenting With Respiratory Distress and Worsening Toe Ischemia.

Authors:  Nayef M Kazzaz; Allecia M Wilson; Ruba Kado; Geoffrey D Barnes; Jason S Knight
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-08       Impact factor: 4.794

Review 6.  The Heart and APS.

Authors:  Mary-Carmen Amigo
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

Review 7.  Morphology of vascular, renal, and heart lesions in the antiphospholipid syndrome: relationship to pathogenesis.

Authors:  M C Amigo; R García-Torres
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.686

Review 8.  Cardiac Manifestations of Antiphospholipid Syndrome With Focus on Its Primary Form.

Authors:  Tamara Kolitz; Shachaf Shiber; Itzhak Sharabi; Asher Winder; Gisele Zandman-Goddard
Journal:  Front Immunol       Date:  2019-05-10       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.